What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

What question did this study set out to answer?

To explore the outcomes of preemptive Rituximab in patients with thrombotic thrombocytopenic purpura and ADAMTS13 deficiency during remission.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Systematic review shows preemptive Rituximab reduced TTP relapses in patients with low ADAMTS13, indicating positive outcomes.

To explore the outcomes of preemptive Rituximab in patients with thrombotic thrombocytopenic purpura and ADAMTS13 deficiency during remission.
Systematic review following PRISMA guidelines
Comprehensive search of PubMed, Cochrane, Embase, and ClinicalTrials.gov
Inclusion of two prospective clinical trials reporting clinical outcomes of Rituximab in TTP patients
Rituximab significantly reduced the median number of TTP relapses and cumulative incidence
56% of patients showed normal ADAMTS13 levels at 3 months post-treatment
Adverse events reported in 21% of patients were low grade and did not lead to drug interruption

Mushtaq et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark